Related Experiment Video
Updated: Mar 19, 2026
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
Evaluation of Endostatin Levels in COVID-19 Patients Admitted to the Emergency Department
Gökhan Akdur1, Okan Bardakci1, Murat Das1
1Canakkale Onsekiz Mart University Faculty of Medicine, Departments of Emergency Medicine, Canakkale, Turkey.
Introduction:
The COVID-19 is defined as a respiratory and endothelial disease caused by Severe Acute Respiratory Syndrome Coronavirus 2. Endostatin is a molecule bound to collagen in the basal membrane of endothelial cells.
Objective:
The aim of this study was to measure the serum endostatin levels of patients diagnosed with COVID-19 in the emergency department.
Methods:
This study was conducted in the emergency department with two groups: COVID-19 PCR-positive patients and healthy adults. Complete blood count, serum biochemistry values, and radiological imaging results were evaluated. Serum endostatin levels were measured from venous blood samples collected during the emergency department visits. Data were analyzed using the SPSS 19.0 software.
Results:
A total of 148 COVID-19 patients and 35 healthy controls were included in the study. The serum endostatin levels of the COVID-19 patient group were significantly lower compared to the healthy control group (p<0.05). The Chest CT Severity Score, 4C-Mortality Score, Quick SOFA, and Quick COVID-19 Severity Index were significantly higher in the patients with a fatal outcome compared to those who survived (p<0.001). Although serum endostatin levels were slightly higher in the fatal outcome group, no statistically significant difference was observed (p>0.05).
Conclusion:
There is no increase in serum endostatin levels in patients with COVID-19 presenting to the emergency department. While a slight increase in endostatin levels was observed in patients with a fatal outcome, it is believed that endostatin will not be effective in predicting prognosis.
